AVROBIO INC (AVRO) Stock Overview
USA - NASDAQ:AVRO - US05455M1009 - Common Stock
AVRO Key Statistics, Chart & Performance
The current stock price of AVRO is 1.4 USD. In the past month the price increased by 1.45%. In the past year, price increased by 52.14%.
AVRO Latest News, Press Relases and Analysis
AVRO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.28 | 398.12B | ||
| AMGN | AMGEN INC | 13.33 | 156.51B | ||
| GILD | GILEAD SCIENCES INC | 15.27 | 146.64B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.62 | 106.95B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.5 | 69.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 63.18B | ||
| ARGX | ARGENX SE - ADR | 89.58 | 50.79B | ||
| INSM | INSMED INC | N/A | 35.35B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.08 | 34.62B | ||
| NTRA | NATERA INC | N/A | 26.40B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.95B | ||
| BIIB | BIOGEN INC | 9.27 | 21.76B |
Related stock screener links
About AVRO
Company Profile
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 78 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The firm is focusing on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies. Its pipeline is comprised of various HSC gene therapy programs, which include AVR-RD-02 for the treatment of Gaucher disease type 1 and type 3; AVR-RD-05 for the treatment of neuronopathic mucopolysaccharidosis type II (MPS-II) or Hunter syndrome; and AVR-RD-03 for the treatment of Pompe disease.
Company Info
AVROBIO INC
100 Technology Square, 6th Floor
Cambridge MASSACHUSETTS 02139 US
CEO: Geoff MacKay
Employees: 78
Phone: 16179148420
AVROBIO INC / AVRO FAQ
What does AVRO do?
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 78 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The firm is focusing on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies. Its pipeline is comprised of various HSC gene therapy programs, which include AVR-RD-02 for the treatment of Gaucher disease type 1 and type 3; AVR-RD-05 for the treatment of neuronopathic mucopolysaccharidosis type II (MPS-II) or Hunter syndrome; and AVR-RD-03 for the treatment of Pompe disease.
Can you provide the latest stock price for AVROBIO INC?
The current stock price of AVRO is 1.4 USD. The price decreased by -1.41% in the last trading session.
Does AVROBIO INC pay dividends?
AVRO does not pay a dividend.
What is the ChartMill technical and fundamental rating of AVRO stock?
AVRO has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is AVRO stock listed?
AVRO stock is listed on the Nasdaq exchange.
Can you provide the PE ratio for AVRO stock?
AVROBIO INC (AVRO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.16).
What is the market capitalization of AVRO stock?
AVROBIO INC (AVRO) has a market capitalization of 62.85M USD. This makes AVRO a Micro Cap stock.
AVRO Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to AVRO. When comparing the yearly performance of all stocks, AVRO is one of the better performing stocks in the market, outperforming 92.57% of all stocks.
AVRO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AVRO. While AVRO has a great health rating, there are worries on its profitability.
AVRO Financial Highlights
Over the last trailing twelve months AVRO reported a non-GAAP Earnings per Share(EPS) of -1.16. The EPS increased by 49.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | 32.82% | ||
| ROE | 34.11% | ||
| Debt/Equity | 0 |
AVRO Forecast & Estimates
8 analysts have analysed AVRO and the average price target is 2.04 USD. This implies a price increase of 45.71% is expected in the next year compared to the current price of 1.4.